Idraparinux and liver enzymes: Observations from the PERSIST trial

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 1, 2003, Pages 61-65

  Reiter, Markus ^a   Bucek, Robert A ^a   Koca, Nihat ^a   Heger, Jürgen ^a   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Deep vein thrombosis; Heparin; Idraparinux; Liver enzymes; Pentasaccharide; Transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; ENOXAPARIN; GAMMA GLUTAMYLTRANSFERASE; HEPARIN DERIVATIVE; IDRAPARINUX; LIVER ENZYME; PENTASACCHARIDE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ALANINE TRANSAMINASE; ANTICOAGULANTS; ASPARTATE AMINOTRANSFERASES; ENOXAPARIN; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPARIN; HUMANS; LIVER; MALE; MIDDLE AGED; OLIGOSACCHARIDES; RANDOMIZED CONTROLLED TRIALS; TRANSFERASES; VENOUS THROMBOSIS; WARFARIN;

EID: 0037279367     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200301000-00011     Document Type: Article

References (20)

1. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232:155-160.
2. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485-1489.
3. Egermayer P. Mortality of untreated deep vein thrombosis following knee arthroscopy [Letter]. Chest 1999; 115:604.
4. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S-193S.
5. Jillella AP, Lutcher CL. Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol 1996; 52:117-119.
6. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann intern Med 2002; 136:210-215.
7. Minar E, Ehringer H, Hirschl M. Transaminase increase: a largely unknown side-effect of heparin treatment. Dtsch Med Wochenschr 1980; 105:1713-1717.
8. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A, Adverse effects of three different forms of heparin therapy: thrombozytopenia, increased transaminases and hyperkalaemia. Eur J Clin Pharmacol 1989; 37:415-418.
9. Guevara A, Labarca J, Gonzàlez-Martin G, Heparin-induced transaminase elevations: a prospective study. Int J Clin Pharmacol 1993; 31:137-141.
10. Olsson R, Jirsab-Bengtsen BM, Korsan-Bengtsen K, Lennartsson J, Waldenstrom J. Serum aminotransferases after low-dose heparin treatment. Short communication. Acta Med Scand 1978; 204:229-230.
11. Sonnenblick M, Oren A, Jacobsonn W. Hyper-transaminasemia with heparin therapy. Br Med J 1975; 3:77.
12. Schwarz KA, Royer G, Kaufman DB, Penner JA. Complications of heparin administration in normal individuals. Am J Haematol 1985; 19:355-363.
13. Pindur G, Heiden M, Kohler M. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers. Arzneimittelforschung 1993; 43:542-547.
14. Christiansen HM, Lassen MR, Borris LC, Sorensen JV, Rahr HB, Jorgensen LN, et al. Biologic tolerance of two different low molecular weight heparins. Semin Thromb Hemost 1991; 17:450-454.
15. Freedman MD, Leese P, Prasad R, Hayden D, An evaluation of the biological response to Fraxiparin (a low molecular weight heparin) in the healthy individual. J Clin Pharmacol 1990; 30:720-727.
16. Harenberg H, Giese C, Dempfle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989; 61:357-362.
17. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267:12528-12538.
18. Herbert JM, Herault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998: 91:4197-4205.
19. Yurdakök M, Tanyel C, Diker S. Heparin-induced increase in serum levels of aminotransferases [Letter]. Am J Hematol 1986; 22:443.
20. Van Amsterdam RG. SanOrg34006. In: Van Amsterdam RG (editor). The PERSIST trial, a multicenter double blind pivotal trial of the dose-effect relationship of subcutaneous SanOrg34006 versus assessor blind oral warfarin in the twelve-week treatment and secondary prophylaxis of venous thromboembolic events in patients with DVT. Oss: Organon; 1999, pp. 24-25.